CenExcel

CenExel is a premier clinical research site network in the United States, specializing in the execution of complex Phase I-IV clinical trials for the pharmaceutical and biotechnology industries. Established in 2018 through the integration of several leading research centers, the company operates 18 'Centers of Excellence' across the country. CenExel is particularly recognized for its deep scientific expertise in central nervous system (CNS) disorders, psychiatry, pain management, and vaccine development. The organization provides a full suite of services, including rapid patient recruitment, protocol consulting, and high-quality data collection. In 2025, CenExel was acquired by the private equity firm BayPine to accelerate its digital transformation and enhance its site performance through AI-enabled tools.